Companies: 10,795·Total market cap: $144.5T
Centessa Pharmaceuticals plc

Centessa Pharmaceuticals plc

CNTANASDAQHealthcare● Active
$39.67
+$0.05(+0.11%)
Market Cap$6.1B
P/E Ratio
52W High$40.26
52W Low$10.95
Overview

Centessa Pharmaceuticals plc (CNTA) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

cnta · stock forecast · 14 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 14 Wall Street analysts in the past 3 months

SellBuy

Buy

14 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
8
Hold
6
Sell
0
Strong Sell
0
Total: 14 · Buy rate: 57.1%

12-Month Price Target

High

$42.00

Consensus

$39.50

-0.6% upside

Low

$38.00

Median: $39 · Last Close: $39.73

The Centessa Pharmaceuticals plc (CNTA) analyst consensus is Buy, based on ratings from 14 Wall Street analysts over the past 3 months. The average 12-month CNTA price target is $39.50, representing -0.6% upside from the current price of $39.73.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $40 (-0.6%)

Consensus Target

$39.50

-0.6% upside

High Target

$42

5.7%

Low Target

$38

-4.4%

Current Price

$39.73

as of today

Based on analyst price targets, the CNTA stock price prediction for the next 12 months ranges from $38 to $42. The consensus CNTA price forecast of $39.50 implies -0.6% upside from the current price of $39.73.

Short-Term Price Prediction

Bull

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$39.760.08%

1-day model range: $39.75–$39.77. Peak: $39.77 (+0.08%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$67+68.3%
2028$94+137.2%
2029$117+195.5%
2030$135+239.1%
2031+269.1%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

64%7%29%
9Buy
1Neutral
4Sell
RSI (14)55.1Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · CNTA · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$39.78SELL
MA 10$39.79SELL
MA 20$39.73BUY
MA 50$39.18BUY
MA 100$32.42BUY
MA 200$28.05BUY
Current $CNTA · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$39.75SELL
EMA 10$39.76SELL
EMA 20$39.63BUY
EMA 50$37.73BUY
EMA 100$34.12BUY
EMA 200$29.23BUY
Current $CNTA · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Wells Fargo2026-04-20
Downgrade ↓
OverweightEqual Weight
Guggenheim2026-04-02
Downgrade ↓
BuyNeutral
Leerink Partners2026-04-01
Downgrade ↓
OutperformMarket Perform
Needham2026-03-31
Downgrade ↓
BuyHold
Wolfe Research2026-03-31
Downgrade ↓
OutperformPeer Perform
Truist Securities2026-01-29
Maintains
BuyBuy
Truist Securities2026-01-08
Maintains
BuyBuy
Chardan Capital2026-01-02
Maintains
BuyBuy
Oppenheimer2025-12-10
Maintains
OutperformOutperform
B. Riley Securities2025-12-01
Maintains
BuyBuy

Wall Street analysts have recently issued updated ratings on Centessa Pharmaceuticals plc (CNTA) stock. Of the recent 42 rating actions, 3 were upgrades and 6 were downgrades. 14 analysts currently cover CNTA.

Analyst Recommendation Trends

Buy ratings101
Hold ratings03↑ +3
Sell ratings00

CNTA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$3M

↓ 98.3% YoY

Revenue Next Year

$25M

↑ 709.7% YoY

EPS This Year

$-1.69

EPS Next Year

$-1.81

↑ 7.3% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast CNTA EPS of $-1.69 for the current fiscal year, based on estimates from 2 analysts. The CNTA revenue forecast is $3M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The CNTA stock forecast is supported by two independent data sources: analyst consensus ratings from 14 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CNTA price target is $39.50 (-0.6% upside), with an analyst consensus of Buy.

The CNTA short-term stock prediction for tomorrow is $39.76 (+0.08%). The CNTA stock price prediction for 2027 estimates an average of $67. The CNTA stock prediction for 2030 projects a range of $134–$135.

Centessa Pharmaceuticals plc trades on NASDAQ under the ticker CNTA. The CNTA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 57% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

CNTA forecast · 8 questions

According to 14 Wall Street analysts, the average 12-month CNTA price target is $39.50, with a high forecast of $42.00 and a low of $38.00. The median price target is shown in the chart above when available. This implies -0.6% potential upside from the current price of $39.73.

CNTA price targetWhat is CNTA price targetCNTA analyst price targetCNTA 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.